Genotype Distribution and Prevalence of Human Papillomavirus in Head and Neck Cancer Samples from Istanbul, Turkey

Human papillomavirus (HPV)-associated tumors account for a significant proportion of head and neck squamous cell carcinomas (HNSCC) in developed countries. In recent years, there has been a rise of HPV infections associated with HNSCC, especially HPV16, which is the most commonly detected type in oral and oropharyngeal cancers. To investigate the frequency of HPV-driven HNSCC among patients living in Turkey, HPV DNA positivity and p16INK4A expression were assessed in primary tumor biopsies (n = 106). Eighteen out of one hundred and six (19%) HNSCC tumors showed p16INK4A overexpression, and 26/106 cases (24.5%) were positive for HPV DNA. Sixteen out of twenty-six samples were positive for both HPV DNA and p16INK4A staining. HPV16 could be isolated from 22/26 samples (84.6%) and was found to be the most frequently detected HPV type. This study represents the largest cohort of Turkish patients with HNSCC characterized according to HPV status and p16INK4A expression. Our data suggest that HPV16 infection, along with smoking, contribute to the development of HNSCC.

Histomorphological and Immunohistochemical Analysis of Gliomas

In the present study, important parameters like frequency distribution of Gliomas, age group of Glioma patients, common sex involved, commonest site of occurrence, clinical presentations, radiological histopathological correlation, p16INK4a expression of the glial tumors are compared with other similar studies. The aim is to find out common age group of Glioma occurrence and it includes higher grades of Astrocytomas. The present study focuses on common symptoms such as head ache, histopathologial correlation and common tumor etc and to study the Histomorphology of Gliomas to evaluate p16INK4a expression in Gliomas to correlate the p16INK4a expression with the WHO grading of Gliomas. Various parameters like age, sex, site, clinical symptoms, radiological correlation and WHO Grading were analysed.p16 IHC was expressed as positive and negative according to its nuclear staining of >25% cells in 10 continuous fields in 40x and it was found that p16 expression was Positive in all Grade 1 Astrocytoma, 3 out of 5 Grade II Astrocytoma and only in one Grade IV Glioblastoma. p16 expression was negative in 2 Grade II Astrocytomas and in 17 Grade IV Gioblastomas and in 2 cases of Myxopapillary Ependymoma.

P16INK4a Expression of Uterine Cervical Biopsy Specimen in SBMCH

Introduction: The cervix is the lower portion of the uterus which connects this organ to the vagina through the endocervical canal. It is divided into the vagina (portiovaginalis) and one that lies above the vaginal vault (supravaginal portion). The outer surface of the portiovaginalis is known as the ectocervix or exocervix and the portion related to the endocervical canal corresponds to the endocervix. Carcinoma cervix accounts for the most common form of cancer by 13% of all the women affected cancers. The P16INK 4a is a tumour suppressor protein which is a CDKN2A gene product, an inhibitor of cyclin dependent kinase (CDK) 4 and 6 which is encoded by tumour suppressor gene INK 4a. Objective: The present study is to evaluate the P16INK 4a expression in cervical biopsy specimens and to correlate it with the histopatholgical findings. Materials and Methods: Cervical biopsy specimens were processed using rotary microtome and tissue blocks cut in sections of 3-5 μm was taken. Results: P16INK4a expression on cervical biopsy specimen showed that those with inflammatory cervical histology, benign lesions of the cervix along with premalignant lesions of cervix are negative for P 16INK4a and all malignant lesions are P 16INK4a positive. Conclusion: Hence P16INK4a immunoreactivity may be used for the diagnosis of neoplastic lesions of the cervix. But in our study, only a small size sample was positive. So, P16INK4a is used as one of the valuable markers for diagnosing neoplastic lesions of the cervix.

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16INK4a

Background Although chemotherapy saves lives, increasing evidence shows that chemotherapy accelerates aging. We previously demonstrated that mRNA expression of p16INK4a, a biomarker of senescence and molecular aging, increased early and dramatically after beginning adjuvant anthracycline-based regimens in early stage breast cancer patients. Here, we determined if changes in p16INK4a expression vary by chemotherapy regimen among early stage breast cancer patients. Methods We conducted a study of stage I-III breast cancer patients receiving adjuvant or neoadjuvant chemotherapy. p16INK4a expression was analyzed prechemotherapy and postchemotherapy (median 6.2 months after the last chemotherapy) in peripheral blood T lymphocytes. Chemotherapy-induced change in p16INK4a expression was compared among regimens. All statistical tests were 2-sided. Results In 146 women, chemotherapy was associated with a statistically significant increase in p16INK4a expression (accelerated aging of 17 years; P < .001). Anthracycline-based regimens were associated with the largest increases (accelerated aging of 23 to 26 years; P ≤ .008). Nonanthracycline-based regimens demonstrated a much smaller increase (accelerated aging of 9 to 11 years; P ≤ .15). In addition to the type of chemotherapy regimen, baseline p16INK4a levels, but not chronologic age or race, were also associated with the magnitude of increases in p16INK4a. Patients with lower p16INK4a levels at baseline were more likely to experience larger increases. Conclusions Our findings suggest that the aging effects of chemotherapy may be influenced by both chemotherapy type and the patient’s baseline p16INK4a level. Measurement of p16INK4a expression is not currently available in the clinic, but nonanthracycline regimens offering similar efficacy as anthracycline regimens might be favored.

Evaluation of the P16INK4a Expression in Cervical Biopsy Specimen SBMCH

In early 1980 human papillomavirus (HPV) were the risk factor and most commonly affects younger women. Many test have developed since then and among that a biomarker test system have developed and clinically evaluated. P16INK4a is used as an important marker for indicating neoplastic transformation for cervical dyplasia. This study was done to evaluate the P16INK4a expression in cervical biopsy in 50 cases. Two cases were identified a P16INK4a positive and remaining 48 didn’t show P16INK4a expression proving the hypothesis that p16INK4a is capable of showing the dysplasia positive cases.